Skip to main content

Marijuana grows at a MedReleaf facility in Markham, Ont., in January, 2016.

Nathan Denette/The Canadian Press

Shares of medical-marijuana producer MedReleaf Corp. tanked Wednesday in its stock market debut amid concerns about lofty valuations in the sector.

The Markham, Ont.-based firm raised $80.7-million in an initial public offering (IPO) through a treasury offering of 8.5 million shares. Early stakeholders sold stock worth $20-million in a secondary offering.

MedReleaf's shares closed at $7.40 on the Toronto Stock Exchange, a 22-per-cent haircut compared with the IPO price of $9.50.

Story continues below advertisement

"It's mostly a sign of fatigue in the industry," said Peter Hodson, the founder and head of research at 5i Research. "The Cannabis Wheaton situation sort of highlighted some of the conflicts that can exist."

Earlier in the week, royalty streaming company Cannabis Wheaton Income Corp. pulled the plug on an $80-million financing with independent investment banks Eight Capital and Canaccord Genuity Group Inc. after it was revealed employees for both dealers owned an 8-per-cent stake in the firm, raising concerns about a conflict of interest.

The financing for the TSX Venture-listed company was later resurrected, with Cannabis Wheaton announcing that boutique dealer Mackie Research Capital Corp. would lead a scaled-down, $50-million offering.

Eight Capital and Canaccord were also involved in the underwriting syndicate that brought MedReleaf to market. GMP Capital Inc. was the co-lead underwriter for the IPO alongside Clarus Securities Inc.

When asked via e-mail whether anyone on the Canaccord capital markets team who worked on the IPO owns any shares in MedReleaf, Canaccord chief executive Dan Daviau replied, "To our knowledge no one owns."

He added that it's "rare" for the firm's capital markets employees to own shares in companies for which they do financings. "We have very strict written rules in place regarding ensuring client priority and conflicts," he wrote.

Mark Attanasio, managing director of investment banking with Eight Capital did not respond to a request for comment.

Story continues below advertisement

And MedReleaf did not respond to a request for comment.

Bruce Campbell, a portfolio manager at StoneCastle Investment Management Inc., bought shares for clients on the MedReleaf IPO but conceded that a lot of the momentum has been sucked out of the sector recently.

"If you look at what's gone on in the last three or four trading days, the [marijuana stocks] have been pretty much straight down," he said.

"The entire industry is frothy because you can't really evaluate these things properly because nobody has any revenues that are really that material," Mr. Hodson said.

MedReleaf had $19-million in revenue for the year ending March 31, 2016, and a net profit of $3.3-million.

Underwriters earned a fee of $5.9-million for bringing the company to market.

Story continues below advertisement

"We've been telling clients to stay away for a long time," Mr. Hodson said.

Report an error Editorial code of conduct
Tickers mentioned in this story
Unchecking box will stop auto data updates
Comments

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • All comments will be reviewed by one or more moderators before being posted to the site. This should only take a few moments.
  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed. Commenters who repeatedly violate community guidelines may be suspended, causing them to temporarily lose their ability to engage with comments.

Read our community guidelines here

Discussion loading ...

Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.
Cannabis pro newsletter